Market Overview:
The global gene delivery system technology drug market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of neurological diseases, cancer, and other applications that are benefitting from gene delivery system technology drugs. In addition, the increasing demand for novel therapeutics and rising investments in R&D are also contributing to the growth of this market. On the basis of type, viral gene delivery system drugs account for a major share of the global gene delivery system technology drug market. This can be attributed to their high efficiency and ability to target specific cells or tissues.
Product Definition:
Gene delivery system technology drug is a method of administering a gene therapy treatment. Gene therapies involve the introduction of new genetic material into cells to treat or prevent disease. The gene delivery system technology drug helps to ensure that the new genetic material is delivered to the target cells in an effective and safe manner.
Viral Gene Delivery System:
Viral gene delivery system, it's usage and growth factor in drug delivery market? Viral particles are capable of carrying genetic material (DNA or RNA) from the site of infection to the host cell. The process is referred to as viral vectorization. This technology has been used for over two decades for research purposes only; however, with recent technological advancements it is now being utilized in various therapeutic areas including oncology and neurology.
Non-viral Gene Delivery System:
Non-viral gene delivery system is a technology used for the efficient and safe transfection of cells with DNA or RNA. It helps in increasing the efficiency of experiments carried out in gene therapy, cell biology, stem cell research, microbiology & biotechnology field. This technology has gained significant traction over past few years owing to its wide range of applications such as protein expression systems and plasmid DNA production.
Application Insights:
The neurological diseases segment dominated the global gene delivery system technology drug market in 2017. This is due to the high prevalence of neurological disorders, such as Parkinson¢â‚¬â„¢s disease, Alzheimer¢â‚¬â„¢s disease, Hunter¢â‚¬â„¢s syndrome and spinal cord injuries. Moreover, increasing government funding for R&D pertaining to gene therapy for neurological disorders will further boost segment growth during the forecast period.
On the other hand, cancer is expected to be one of the fastest growing application segments during the forecast period owing to extensive research & development activities pertaining to oncology by various companies including Intrexon Corporation (acquired by Myriad Genetics), Amgen Inc., Pfizer Inc., and Eli Lilly and Company over recent years.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of clinical trial participants and research institutes involved in developing novel gene therapy approaches. Moreover, an increase in R&D investments by companies and government for drug development is expected to fuel growth over the forecast period. The U.S.-based company, Aracare acquired exclusive commercialization rights for LentiGlobin from Novartis AG & Co., Ltd (Japan). This product is currently being evaluated in phase I/IIa clinical trials for treatment of Leber congenital amaurosis (LCA) which affects 1 out of 10,000 births globally.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period due to rising disposable income coupled with growing awareness among people about advanced therapies resulting into higher adoption rate compared with other regions.
Growth Factors:
- Increasing demand for gene delivery technology drugs due to rising prevalence of chronic diseases such as cancer, diabetes, and heart diseases.
- Growing investment by pharmaceutical companies in R&D of novel gene delivery technology drugs for the treatment of various chronic diseases.
- Rising number of clinical trials being conducted on gene delivery technology drugs for the treatment of various chronic diseases.
- increasing use of targeted drug delivery systems to improve the efficacy and safety profile of gene therapy treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Delivery System Technology Drug Market Research Report
By Type
Viral Gene Delivery System, Non-viral Gene Delivery System
By Application
Neurological Diseases, Cancer, Other
By Companies
Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
215
Number of Tables & Figures
151
Customization Available
Yes, the report can be customized as per your need.
Global Gene Delivery System Technology Drug Market Report Segments:
The global Gene Delivery System Technology Drug market is segmented on the basis of:
Types
Viral Gene Delivery System, Non-viral Gene Delivery System
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Neurological Diseases, Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Novartis
- Gilead Sciences
- Sarepta Therapeutics
- Alnylam Pharmaceuticals
- Amgen
- Spark Therapeutics
- Akcea Therapeutics
- bluebird bio
- Sunway Biotech
- SIBIONO
- AnGes
- Orchard Therapeutics
- Human Stem Cells Institute
Highlights of The Gene Delivery System Technology Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Viral Gene Delivery System
- Non-viral Gene Delivery System
- By Application:
- Neurological Diseases
- Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Delivery System Technology Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A gene delivery system technology drug is a medication that uses a vector to transport genes to specific locations in the body. This type of medication can help treat diseases by delivering genes that help repair or replace damaged cells, tissues, or organs.
Some of the key players operating in the gene delivery system technology drug market are Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, Spark Therapeutics, Akcea Therapeutics, bluebird bio, Sunway Biotech, SIBIONO, AnGes, Orchard Therapeutics, Human Stem Cells Institute.
The gene delivery system technology drug market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gene Delivery System Technology Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Gene Delivery System Technology Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Gene Delivery System Technology Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Gene Delivery System Technology Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Gene Delivery System Technology Drug Market Size & Forecast, 2018-2028 4.5.1 Gene Delivery System Technology Drug Market Size and Y-o-Y Growth 4.5.2 Gene Delivery System Technology Drug Market Absolute $ Opportunity
Chapter 5 Global Gene Delivery System Technology Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gene Delivery System Technology Drug Market Size Forecast by Type
5.2.1 Viral Gene Delivery System
5.2.2 Non-viral Gene Delivery System
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gene Delivery System Technology Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gene Delivery System Technology Drug Market Size Forecast by Applications
6.2.1 Neurological Diseases
6.2.2 Cancer
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gene Delivery System Technology Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gene Delivery System Technology Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gene Delivery System Technology Drug Analysis and Forecast
9.1 Introduction
9.2 North America Gene Delivery System Technology Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gene Delivery System Technology Drug Market Size Forecast by Type
9.6.1 Viral Gene Delivery System
9.6.2 Non-viral Gene Delivery System
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gene Delivery System Technology Drug Market Size Forecast by Applications
9.10.1 Neurological Diseases
9.10.2 Cancer
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gene Delivery System Technology Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Gene Delivery System Technology Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gene Delivery System Technology Drug Market Size Forecast by Type
10.6.1 Viral Gene Delivery System
10.6.2 Non-viral Gene Delivery System
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gene Delivery System Technology Drug Market Size Forecast by Applications
10.10.1 Neurological Diseases
10.10.2 Cancer
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gene Delivery System Technology Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gene Delivery System Technology Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gene Delivery System Technology Drug Market Size Forecast by Type
11.6.1 Viral Gene Delivery System
11.6.2 Non-viral Gene Delivery System
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gene Delivery System Technology Drug Market Size Forecast by Applications
11.10.1 Neurological Diseases
11.10.2 Cancer
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gene Delivery System Technology Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Gene Delivery System Technology Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gene Delivery System Technology Drug Market Size Forecast by Type
12.6.1 Viral Gene Delivery System
12.6.2 Non-viral Gene Delivery System
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gene Delivery System Technology Drug Market Size Forecast by Applications
12.10.1 Neurological Diseases
12.10.2 Cancer
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gene Delivery System Technology Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gene Delivery System Technology Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gene Delivery System Technology Drug Market Size Forecast by Type
13.6.1 Viral Gene Delivery System
13.6.2 Non-viral Gene Delivery System
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gene Delivery System Technology Drug Market Size Forecast by Applications
13.10.1 Neurological Diseases
13.10.2 Cancer
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gene Delivery System Technology Drug Market: Competitive Dashboard
14.2 Global Gene Delivery System Technology Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Novartis
14.3.3 Gilead Sciences
14.3.4 Sarepta Therapeutics
14.3.5 Alnylam Pharmaceuticals
14.3.6 Amgen
14.3.7 Spark Therapeutics
14.3.8 Akcea Therapeutics
14.3.9 bluebird bio
14.3.10 Sunway Biotech
14.3.11 SIBIONO
14.3.12 AnGes
14.3.13 Orchard Therapeutics
14.3.14 Human Stem Cells Institute